BioArctic publishes the Annual Report for 2017

Stockholm, Sweden, April 24, 2018 – BioArctic AB (publ.) (Nasdaq Stockholm: BIOA B) announced today that the Annual Report for the 2017 fiscal year has been published.

The Annual Report is attached and can also be downloaded from the company’s website, www.bioarctic.com (investors/financial reports).

For more information, please contact:
Christina Astrén, IR and Communications Director
E-mail: christina.astren@bioarctic.se

Telephone: + 46 70 835 43 36

This information is information that BioArctic AB (publ.) is obliged to disclose pursuant to the EU Market Abuse Regulations and the Swedish Securities Market Act. The information was released for public disclosure through the agency of the contact person above at 10.00 am CET on April 24, 2018.

About BioArctic
BioArctic AB (publ) is a Swedish research based biopharma company focusing on disease modifying treatments and reliable biomarkers and diagnostics for neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease. The company also develops a potential treatment for Complete Spinal Cord Injury. BioArctic focuses on innovative treatments in areas with high unmet medical needs. Collaborations with universities are of great importance to the company together with our strategically important global partners in the Alzheimer (Eisai) and Parkinson (AbbVie) projects. The project portfolio is a combination of fully funded projects run in partnership with global pharmaceutical companies and innovative in-house projects with significant market and out-licensing potential.

BioArctic’s B-share is listed on Nasdaq Stockholm Mid Cap (Stockholm Nasdaq: BIOA B). www.bioarctic.com

Tags:

About Us

BioArctic AB is a Swedish research based biopharma company focusing on disease modifying treatments and reliable biomarkers and diagnostics for neurodegenerative diseases, such as Alzheimer’s disease and Parkinson’s disease. The company also develops a potential treatment for Complete Spinal Cord Injury. BioArctic focuses on innovative treatments in areas with high unmet medical needs. Collaborations with universities are of great importance to the company together with our strategically important global partners in the Alzheimer (Eisai) and Parkinson (AbbVie) projects. The project portfolio is a combination of fully funded projects run in partnership with global pharmaceutical companies and innovative in-house projects with significant market- and out-licensing potential. www.bioarctic.se